Pioglitazone/microRNA‑141/FOXA2: A novel axis in pancreatic β‑cells proliferation and insulin secretion

Yu,Xin; Zhong,Liyong

doi:10.3892/mmr.2018.8813

Pioglitazone/microRNA‑141/FOXA2: A novel axis in pancreatic β‑cells proliferation and insulin secretion

Authors:
- Xin Yu
- Liyong Zhong
View Affiliations

Affiliations: Department of Endocrinology, Beijing Tian Tan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: March 28, 2018 https://doi.org/10.3892/mmr.2018.8813
Pages: 7931-7938

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) are considered to be effective, post‑transcriptional regulators in the pathophysiology of type 2 diabetes (T2D) and promising treatment targets. However, the function of miR‑141 remains to be elucidated. In the present study, upregulation of miR‑141 was demonstrated in diabetic mice and elderly diabetic patients. Using reverse transcriptase‑quantitative polymerase chain reaction, luciferase reporter assays and western blotting, forkhead box A2 (FOXA2) was identified as a direct target gene of miR‑141. The potential role of miRNA‑141 or FOXA2 was evaluated by overexpressing or silencing miR‑141 or FOXA2, respectively. The increased expression of miR‑141 resulted in impaired glucose‑stimulated insulin secretion (GSIS) and INS‑1 β cell proliferation. In addition, miR‑141 silencing in MIN6 pseudoislets or INS‑1 β cells led to reduced T2D‑associated damage. Furthermore, the expression of miR‑141 may be corrected by treatment with pioglitazone, which is widely used for insulin resistance therapy. The present study also demonstrated the mechanism by which miR‑141 regulated GSIS and proliferation through FOXA2. Overexpression of FOXA2 in MIN6 pseudoislets increased the effect of the miR‑141 inhibitor on GSIS. FOXA2 effectively reversed the effect of miR‑141 overexpression on β cell proliferation. In conclusion, the results of the present study indicate that the pioglitazone/miR‑141/FOXA2 axis may represent a promising target mechanism for T2D treatment.

View Figures

View References

1	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
2	Wienholds E and Plasterk RH: MicroRNA function in animal development. FEBS Lett. 579:5911–5922. 2005. View Article : Google Scholar : PubMed/NCBI
3	Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, Vatner DE, Vatner SF and Abdellatif M: Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 104:879–886. 2009. View Article : Google Scholar : PubMed/NCBI
4	Xie H, Lim B and Lodish HF: MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes. 58:1050–1057. 2009. View Article : Google Scholar : PubMed/NCBI
5	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
6	Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y and Su L: MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci. 55:2365–2372. 2010. View Article : Google Scholar : PubMed/NCBI
7	Xu L, Li Q, Xu D, Wang Q, An Y, Du Q, Zhang J, Zhu Y and Miao Y: hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Int J Oncol. 44:459–466. 2014. View Article : Google Scholar : PubMed/NCBI
8	Chen B, Huang T, Jiang J, Lv L, Li H and Xia S: miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. Mol Cell Biochem. 388:211–218. 2014. View Article : Google Scholar : PubMed/NCBI
9	Tamagawa S, Beder LB, Hotomi M, Gunduz M, Yata K, Grenman R and Yamanaka N: Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med. 33:879–886. 2014. View Article : Google Scholar : PubMed/NCBI
10	Weir GC and Bonner-Weir S: Sleeping islets and the relationship between β-cell mass and function. Diabetes. 60:2018–2019. 2011. View Article : Google Scholar : PubMed/NCBI
11	Maris M, Ferreira GB, D'Hertog W, Cnop M, Waelkens E, Overbergh L and Mathieu C: High glucose induces dysfunction in insulin secretory cells by different pathways: A proteomic approach. J Proteome Res. 9:6274–6287. 2010. View Article : Google Scholar : PubMed/NCBI
12	Chatterjee S and Davies MJ: Current management of diabetes mellitus and future directions in care. Postgrad Med J. 91:612–621. 2015. View Article : Google Scholar : PubMed/NCBI
13	Kaul K, Apostolopoulou M and Roden M: Insulin resistance in type 1 diabetes mellitus. Metabolism. 64:1629–1639. 2015. View Article : Google Scholar : PubMed/NCBI
14	Sergienko VA: Insulin resistance and arterial stiffness in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy. Zh Nevrol Psikhiatr Im S S Korsakova. 114:11–15. 2014.(In Russian). PubMed/NCBI
15	Polsky S and Ellis SL: Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 22:277–282. 2015. View Article : Google Scholar : PubMed/NCBI
16	Fakhrzadeh H, Sharifi F, Alizadeh M, Arzaghi SM, Tajallizade-Khoob Y, Tootee A, Alatab S, Mirarefin M, Badamchizade Z and Kazemi H: Relationship between insulin resistance and subclinical atherosclerosis in individuals with and without type 2 diabetes mellitus. J Diabetes Metab Disord. 15:412016. View Article : Google Scholar : PubMed/NCBI
17	Iversen DS, Støy J, Kampmann U, Voss TS, Madsen LR, Møller N and Ovesen PG: Parity and type 2 diabetes mellitus: A study of insulin resistance and β-cell function in women with multiple pregnancies. BMJ Open Diabetes Res Care. 4:e0002372016. View Article : Google Scholar : PubMed/NCBI
18	Ao C, Huo Y, Qi L, Xiong Z, Xue L and Qi Y: Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB. Cell Biol Int. 34:723–730. 2010. View Article : Google Scholar : PubMed/NCBI
19	Wan H, Yuan Y, Qian A, Sun Y and Qiao M: Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells. Biomed Pharmacother. 62:466–472. 2008. View Article : Google Scholar : PubMed/NCBI
20	Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C and Fantozzi R: Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol. 530:70–80. 2006. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Lin L, Liang H, Wang Y, Yin X, Hu Y, Huang J, Ren T, Xu H, Zheng L and Chen X: microRNA-141 inhibits cell proliferation and invasion and promotes apoptosis by targeting hepatocyte nuclear factor-3β in hepatocellular carcinoma cells. BMC Cancer. 14:8792014. View Article : Google Scholar : PubMed/NCBI
23	Xue J, Niu YF, Huang J, Peng G, Wang LX, Yang YH and Li YQ: miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3. Tumour Biol. 35:12103–12107. 2014. View Article : Google Scholar : PubMed/NCBI
24	Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, Li Q, Zhang Y, Ding Y, Chen B and Chen L: MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 9:e883932014. View Article : Google Scholar : PubMed/NCBI
25	Lee CS, Sund NJ, Vatamaniuk MZ, Matschinsky FM, Stoffers DA and Kaestner KH: Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. Diabetes. 51:2546–2551. 2002. View Article : Google Scholar : PubMed/NCBI
26	Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharfmann R, Rutter GA and Van Obberghen E: MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem. 282:19575–19588. 2007. View Article : Google Scholar : PubMed/NCBI
27	Yu T, Lu XJ, Li JY, Shan TD, Huang CZ, Ouyang H, Yang HS, Xu JH, Zhong W, Xia ZS and Chen QK: Overexpression of miR-429 impairs intestinal barrier function in diabetic mice by down-regulating occludin expression. Cell Tissue Res. 366:341–352. 2016. View Article : Google Scholar : PubMed/NCBI
28	Yang X, Tao Z, Zhu Z, Liao H, Zhao Y and Fan H: MicroRNA-593-3p regulates insulin-promoted glucose consumption by targeting Slc38a1 and CLIP3. J Mol Endocrinol. 57:211–222. 2016. View Article : Google Scholar : PubMed/NCBI
29	Chen Y, Tian L, Wan S, Xie Y, Chen X, Ji X, Zhao Q, Wang C, Zhang K, Hock JM, et al: MicroRNA-17-92 cluster regulates pancreatic beta-cell proliferation and adaptation. Mol Cell Endocrinol. 437:213–223. 2016. View Article : Google Scholar : PubMed/NCBI
30	Zhuo S, Yang M, Zhao Y, Chen X, Zhang F, Li N, Yao P, Zhu T, Mei H, Wang S, et al: MicroRNA-451 negatively regulates hepatic glucose production and glucose homeostasis by targeting glycerol kinase-mediated gluconeogenesis. Diabetes. 65:3276–3288. 2016. View Article : Google Scholar : PubMed/NCBI
31	Fu X, Dong B, Tian Y, Lefebvre P, Meng Z, Wang X, Pattou F, Han W, Wang X, Lou F, et al: MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J Clin Invest. 125:2497–2509. 2015. View Article : Google Scholar : PubMed/NCBI
32	Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, Jandeleit-Dahm K, Burns WC, Thomas MC, Cooper ME and Kantharidis P: miR-200a prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes. 60:280–287. 2011. View Article : Google Scholar : PubMed/NCBI
33	Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T and Kobayashi M: Effects of pioglitazone on suppressor of cytokine signaling 3 expression: Potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes. 56:795–803. 2007. View Article : Google Scholar : PubMed/NCBI
34	Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, Kawahara J, Ueno E, Sasaoka T, Ishibashi O and Kobayashi M: Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes. 50:1083–1092. 2001. View Article : Google Scholar : PubMed/NCBI
35	Hu SH, Jiang T, Yang SS and Yang Y: Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. Exp Clin Endocrinol Diabetes. 121:220–224. 2013. View Article : Google Scholar : PubMed/NCBI
36	Sebastiani G, Po A, Miele E, Ventriglia G, Ceccarelli E, Bugliani M, Marselli L, Marchetti P, Gulino A, Ferretti E and Dotta F: MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol. 52:523–530. 2015. View Article : Google Scholar : PubMed/NCBI